Literature DB >> 23053453

Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers.

Carlo Bartolozzi1, Valentina Battaglia, Irene Bargellini, Elena Bozzi, Daniela Campani, Luca Emanuele Pollina, Franco Filipponi.   

Abstract

PURPOSE: To analyze Gd-EOB-DTPA-enhanced magnetic resonance (MR) findings of nodules (low-grade dysplastic nodules-LGDNs; high-grade dysplastic nodules-HGDN, and hepatocellular carcinoma-HCC), histologically identified on cirrhotic, explanted livers.
METHODS: IRB approval was obtained for this study. Thirty-four patients underwent Gd-EOB-DTPA-enhanced MR examinations (1.5T system), that included 20-min delayed hepatobiliary (HB) phase imaging, before undergoing orthotopic liver transplantation (OLT; mean time MR-OLT: 2.7 months). A total of 102 hepatic nodules were identified and analyzed at histopathological examination, and classified as LGDN, HGDN, and HCC. Two radiologists by consensus performed a quantitative (enhancement ratios, ERs) and a qualitative analyses of signal intensities of identified nodules on vascular dynamic phases (30-35 s after injection-arterial phase; 180-190 s after injection late phase) and on HB phases. Correlation between nodules MR patterns and histological classification was analyzed by means of dedicated statistical software.
RESULTS: No differences were appreciable among ERs of HGDN and HCCs on HB phase (P > 0.001). Lesions' enhancement on vascular dynamic and on HB phases significantly correlated to histological classification of nodules (P < 0.0001). Nodular hyperintensity on arterial phase and hypointensity on late phase were highly predictive for HCC (PPV 100%), with a moderate sensitivity (72.5%). Nodular hypointensity on HB phase was detected on 39/40 HCCs (sensitivity 97.5%) and in 21/30 HGDNs, whereas no LGDN showed it.
CONCLUSIONS: Hyperenhancement on arterial phase and hypointensity on late phase are the most specific clues for the diagnosis of HCC. Hypointensity on HB phase shows a PPV of 100% in suggesting nodular premalignancy/malignancy, independently from nodular dynamic vascular enhancement.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23053453     DOI: 10.1007/s00261-012-9952-9

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  29 in total

1.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

2.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

3.  Time to update radiological criteria for non-invasive diagnosis of hepatocellular carcinoma.

Authors:  Sanjay Saini; Daniel S Pratt
Journal:  Hepatol Int       Date:  2014-11-02       Impact factor: 6.047

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.

Authors:  Katsuhiro Sano; Tomoaki Ichikawa; Utaroh Motosugi; Shintaro Ichikawa; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

Review 6.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

7.  [Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria].

Authors:  A Kircher; G Bongartz; E M Merkle; C J Zech
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

8.  Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.

Authors:  Chiara Briani; Marco Di Pietropaolo; Massimo Marignani; Francesco Carbonetti; Paola Begini; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2018-09

Review 9.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 10.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.